Patent ID: 11911513
Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 10:
11. The method of claim 6, wherein in the extended release platform, the pharmaceutical composition is composed of a drug-containing layer and a coating membrane, the drug containing layer is composed of 40 wt % of levodopa, 10.8 wt % of carbidopa, 20 wt % of microcrystalline cellulose, 18.7 wt % of mannitol, 5 wt % of citric acid, 5 wt % of hydroxypropyl methyl cellulose sodium and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the coating membrane is composed of 50 wt % of cellulose acetate membrane and 50 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; the weight of the coating membrane is 2.0% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer and a coating membrane, the drug-containing layer is composed of 38 wt % of levodopa, 50 wt % of microcrystalline cellulose, 10 wt % of hydroxypropyl methyl cellulose and 2 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the coating membrane is composed of 50 wt % of cellulose acetate membrane and 50 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane, and the weight of the coating membrane is 4.5% of the weight of tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer and a coating membrane, the drug-containing layer comprises 19.5 wt % of levodopa, 20 wt % of carbidopa, 50 wt % of mannitol, 10 wt % of citric acid and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the coating membrane is composed of 50 wt % of cellulose acetate membrane and 50 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane, and the weight of the coating membrane is 4.5% of the weight of tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, and a coating membrane, and the drug-containing layer is composed of 40 wt % of levodopa, 10.8 wt % of carbidopa, 31 wt % of hydroxypropyl cellulose, 12.7 wt % of mannitol, 5 wt % of citric acid and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF or 9H4 XF, 5 wt % of povidone K30, 39 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; the weight of the coating membrane is 2.0%, 4.0% or 5.0% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, and a coating membrane, the drug-containing layer is composed of 40 wt % of levodopa, 10.8 wt % of carbidopa, 31 wt % of hydroxypropyl cellulose, 12.7 wt % of mannitol, 5 wt % of citric acid and 0.5 wt % of povidone K30, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 5 wt % of povidone K30, 39 wt % of sorbitol, 0.5 wt % of iron oxide red, and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 60 wt % of cellulose acetate membrane and 40% copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 5.0% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, and a coating membrane, the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 16 wt % of mannitol, 5 wt % of povidone K30, and 1 wt % of magnesium stearate, 1 wt % of mint flavor and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4 XF, 10 wt % of povidone K30, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 60 wt % of cellulose acetate membrane and 40 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.2%, 6.7% or 9.7% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, and a coating membrane, the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 16 wt % of mannitol, 5 wt % of povidone K30, 1 wt % of magnesium stearate, 1 wt % of mint flavor and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of povidone K30, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.6% or 7.9% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, and a coating membrane, the drug-containing layer is composed of 70 wt % of levodopa, 9 wt % of mannitol, 20 wt % of povidone K30, 1 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 85 wt % of sodium carboxymethyl cellulose, 3 wt % of povidone K30, 5 wt % of sorbitol, 5 wt % of iron oxide red and 2 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.5% of the weight of the tablet core;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat, the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 16 wt % of mannitol, 5 wt % of povidone K30, 1 wt % of magnesium stearate, 1 wt % of mint flavor and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of povidone K30, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.8% or 7.7% of the weight of the tablet core, the overcoat is composed of 23.78 wt % of levodopa, 64.22 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 1 wt % of aspartame and 1 wt % of mint flavor immediate release composition, wherein the weight percentage is the weight percentage of each component of the overcoat, and the weight gain of the overcoat relative to the tablet core is 13.2% and 12.9% by weight, respectively;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat, the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 17 wt % of mannitol, 5 wt % of povidone K30, 1 wt % of magnesium stearate and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 60 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of povidone K30, 26 wt % of sorbitol, 2 wt % of iron oxide red and 2 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.8% of the weight of the tablet core; the overcoat is composed of 93 wt % of carbidopa (CD), 2 wt % of hydroxypropyl cellulose and 5 wt % of aspartame immediate release composition, wherein the weight percentage is the weight percentage of each component of the overcoat, and the weight gain of the overcoat relative to the tablet core is 13.2% by weight;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat, the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 12 wt % of mannitol, 5 wt % of povidone K30, 5 wt % of mint flavor, 1 wt % of aspartame and 1 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 40 wt % of sodium carboxymethyl cellulose 7H4XF, 20 wt % of povidone K30, 36 wt % of sorbitol, 3.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 4.8% of the weight of the tablet core; the overcoat is composed of 75 wt % of levodopa, 20 wt % of hydroxypropyl cellulose and 5 wt % of mint flavor immediate release composition, wherein the weight percentage is the weight percentage of each component of the overcoat, and the weight gain of the overcoat relative to the tablet core is 13.2% by weight;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat, the drug-containing layer is composed of 62.5 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 4.5 wt % of mannitol, 0.1 wt % of mint flavor, 0.9 wt % of aspartame and 1 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 6.5% of the weight of the tablet core, the overcoat is composed of 62.15 wt % of levodopa, 26.85 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 0.9 wt % of aspartame and 0.1 wt % of mint flavor immediate release composition, wherein the weight percentage is the weight percentage of each component of the overcoat, and the weight gain of the overcoat relative to the tablet core is 21.0% by weight;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat, the drug-containing layer is composed of 46.9 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 20.1 wt % of mannitol, 0.1 wt % of mint flavor, 0.9 wt % of aspartame and 1 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; and the weight of the coating membrane is 6.5% of the weight of the tablet core, the overcoat is composed of 62.15 wt % of levodopa, 26.85 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 0.9 wt % of aspartame and 0.1 wt % of mint flavor immediate release composition, wherein the weight percentage is the weight percentage of each component of the overcoat, and the weight gain of the overcoat relative to the tablet core is 15.7% by weight;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat; wherein the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 17 wt % of mannitol, 5 wt % of povidone K30, 1 wt % of magnesium stearate and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; wherein, the cellulose acetate is a cellulose acetate membrane containing 39.8 wt % of acetyl, and the weight of the coating membrane is 5.9% of the weight of the tablet core; and, the overcoat is composed of 24 wt % of levodopa, 65 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose and 1 wt % of aspartame, wherein the weight percentage is the weight percentage of each component of the overcoat, the weight of the overcoat is 13.1% of the total weight of the tablet core and the coating membrane;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat; the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 22 wt % of mannitol, 0.9 wt % of aspartame, 1 wt % of magnesium stearate and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; wherein, the cellulose acetate is a cellulose acetate membrane containing 39.8 wt % of acetyl, and the weight of the coating membrane is 6.5% of the weight of the tablet core; and, the overcoat is composed of 54 wt % of levodopa, 35 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 0.9 wt % of aspartame and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the overcoat, the weight of the overcoat is 13.1% of the total weight of the tablet core and the coating membrane;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat; the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 22 wt % of mannitol, 0.9 wt % of aspartame, 1 wt % of magnesium stearate and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; wherein, the cellulose acetate is a cellulose acetate membrane containing 39.8 wt % of acetyl, and the weight of the coating membrane is 7.0% of the weight of the tablet core; and, the overcoat is composed of 42.8 wt % of levodopa, 46.2 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 0.9 wt % of aspartame and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the overcoat, the weight of the overcoat is 13.1% of the total weight of the tablet core and the coating membrane;
or, the pharmaceutical composition is composed of a drug-containing layer, an osmotic push layer, a coating membrane and an overcoat; the drug-containing layer is composed of 45 wt % of levodopa, 31 wt % of hydroxypropyl cellulose, 22 wt % of mannitol, 0.9 wt % of aspartame, 1 wt % of magnesium stearate and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the drug-containing layer; the osmotic push layer is composed of 55 wt % of sodium carboxymethyl cellulose 7H4XF, 10 wt % of hydroxypropyl cellulose, 34 wt % of sorbitol, 0.5 wt % of iron oxide red and 0.5 wt % of magnesium stearate, wherein the weight percentage is the weight percentage of each component of the osmotic push layer; the coating membrane is composed of 70 wt % of cellulose acetate membrane and 30 wt % of copovidone VA64, wherein the weight percentage is the weight percentage of each component of the coating membrane; wherein, the cellulose acetate is a cellulose acetate membrane containing 39.8 wt % of acetyl, and the weight of the coating membrane is 9.0% of the weight of the tablet core; and, the overcoat is composed of 28.2 wt % of levodopa, 60.8 wt % of carbidopa, 10 wt % of hydroxypropyl cellulose, 0.9 wt % of aspartame and 0.1 wt % of mint flavor, wherein the weight percentage is the weight percentage of each component of the overcoat, the weight of the overcoat is 13.1% of the total weight of the tablet core and the coating membrane.